,30,38 Importantly, the current investigation extends these findings to suggest that CDK5 hyperactivation under glucotoxicity may contribute to the loss of beta cell function and insulin resistance, proposing CDK5 inhibitors as potential candidates for the treatment of T2D. This evidence concerns the gene CDK5 and type 2 diabetes mellitus.